The role of IL-6 trans-signaling in vascular leakage: Implications for ovarian hyperstimulation syndrome in a murine model

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 3, 2013, Pages

  Wei, Lin Hung ^a   Chou, Chia Hung ^a   Chen, Min Wei ^a   Rose John, Stefan ^b   Kuo, Min Liang ^a   Chen, Shee Uan ^a,c   Yang, Yu Shih ^a,c  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b UNIVERSITY OF KIEL   (Germany)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE C; SOLUBLE INTERLEUKIN 6 RECEPTOR ALPHA; STAT3 PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; GRANULOSA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; LUTEAL CELL; MAJOR CLINICAL STUDY; NONHUMAN; OVARY HYPERSTIMULATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; VASCULAR DISEASE; VASCULAR LEAKAGE;

ANIMALS; CAPILLARY PERMEABILITY; CHORIONIC GONADOTROPIN; CYTOKINE RECEPTOR GP130; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; FEMALE; FOLLICLE STIMULATING HORMONE; FOLLICULAR FLUID; GRANULOSA CELLS; HORMONES; HUMANS; INTERLEUKIN-6; MICE; MICE, INBRED ICR; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION INDUCTION; PROTEIN KINASE C; RECEPTORS, INTERLEUKIN-6; REPRODUCTIVE CONTROL AGENTS; RISK FACTORS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84874830783     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-3462     Document Type: Article

References (40)

1. Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update. 2002;8:559-577. (Pubitemid 35452781)
2. Delvigne A, Rozenberg S. Review of clinical course and treatment of ovarian hyperstimulation syndrome (OHSS). Hum Reprod Update. 2003;9:77-96. (Pubitemid 36305585)
3. Grossman LC, Michalakis KG, Browne H, Payson MD, Segars JH. The pathophysiology of ovarian hyperstimulation syndrome: an unrecognized compartment syndrome. Fertil Steril. 2010;94:1392-1398.
4. Chen CD, Chen HF, Lu HF, Chen SU, Ho HN, Yang YS. Value of serum and follicular fluid cytokine profile in the prediction of moderate to severe ovarian hyperstimulation syndrome. Hum Reprod. 2000;15:1037-1042.
5. Barak V, Elchalal U, Edelstein M, Kalickman I, Lewin A, Abramov Y. Interleukin-18 levels correlate with severe ovarian hyperstimulation syndrome. Fertil Steril. 2004;82:415-420. (Pubitemid 39092043)
6. Rizk B, Aboulghar M, Smitz J, Ron-El R. The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome. Hum Reprod Update. 1997;3:255-266. (Pubitemid 27437930)
7. Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cytokines and gp130. Blood. 1995;86:1243-1254.
8. Rose-John S, Scheller J, Elson G, Jones SA. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol. 2006;80:227-236. (Pubitemid 44835496)
9. Peters M, Muller AM, Rose-John S. Interleukin-6 and soluble interleukin-6 receptor: direct stimulation of gp130 and hematopoiesis. Blood. 1998;92:3495-3504. (Pubitemid 28525172)
10. Lo CW, Chen MW, Hsiao M, et al. IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer. Cancer Res. 2011;71:424-434.
11. Chalaris A, Garbers C, Rabe B, Rose-John S, Scheller J. The soluble interleukin 6 receptor: generation and role in inflammation and cancer. Eur J Cell Biol. 2011;90:484-494.
12. Friedlander MA, Loret de Mola JR, Goldfarb JM. Elevated levels of interleukin-6 in ascites and serum from women with ovarian hyperstimulation syndrome. Fertil Steril. 1993;60:826-833. (Pubitemid 23324771)
13. Geva E, Lessing JB, Lerner-Geva L, Azem F, Yovel I, Amit A. Elevated levels of interleukin-6 in the follicular fluid at the time of oocyte retrieval for in vitro fertilization may predict the development of early-form ovarian hyperstimulation syndrome. Fertil Steril. 1997;68:133-137. (Pubitemid 27283730)
14. Chen SU, Chou CH, Lin CW, et al. Signal mechanisms of vascular endothelial growth factor and interleukin-8 in ovarian hyperstimulation syndrome: dopamine targets their common pathways. Hum Reprod. 2010;25:757-767.
15. Aboulghar MA, Mansour RT, Serour GI, El Helw BA, Shaarawy M. Elevated levels of interleukin-2, soluble interleukin-2 receptor α, interleukin-6, soluble interleukin-6 receptor and vascular endothelial growth factor in serum and ascitic fluid of patients with severe ovarian hyperstimulation syndrome. Eur J Obstet Gynecol Reprod Biol. 1999;87:81-85.
16. Asch RH, Li HP, Balmaceda JP, Weckstein LN, Stone SC. Severe ovarian hyperstimulation syndrome in assisted reproductive technology: definition of high risk groups. Hum Reprod. 1991;6:1395-1399.
17. Albert C, Garrido N, Mercader A, et al. The role of endothelial cells in the pathogenesis of ovarian hyperstimulation syndrome. Mol Hum Reprod. 2002;8:409-418. (Pubitemid 34567918)
18. Oakley OR, Kim H, El-Amouri I, et al. Periovulatory leukocyte infiltration in the rat ovary. Endocrinology. 2010;151:4551-4559.
19. Chalaris A, Rabe B, Paliga K, et al. Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory transsignaling function of neutrophils. Blood. 2007;110:1748-1755. (Pubitemid 47443884)
20. Wei LH, Kuo ML, Chen CA, et al. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene. 2003;22:1517-1527.
21. Jones SA, Scheller J, Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest. 2011;121: 3375-3383.
22. Atreya R, Mudter J, Finotto S, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat Med. 2000;6:583-588. (Pubitemid 30305911)
23. Nowell MA, Richards PJ, Horiuchi S, et al. Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130. J Immunol. 2003;171:3202-3209. (Pubitemid 37093546)
24. Becker C, Fantini MC, Schramm C, et al. TGF-β suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity. 2004;21:491-501. (Pubitemid 39370505)
25. Richards JS, Liu Z, Shimada M. Immune-like mechanisms in ovulation. Trends Endocrinol Metab. 2008;19:191-196. (Pubitemid 351993011)
26. McClure N, Healy DL, Rogers PA, et al. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet. 1994;344:235-236. (Pubitemid 24229013)
27. Villasante A, Pacheco A, Ruiz A, Pellicer A, Garcia-Velasco JA. Vascular endothelial cadherin regulates vascular permeability: implications for ovarian hyperstimulation syndrome. J Clin Endocrinol Metab. 2007;92:314-321. (Pubitemid 46067549)
28. Rodewald M, Herr D, Duncan WC, et al. Molecular mechanisms of ovarian hyperstimulation syndrome: paracrine reduction of endothelial claudin 5 by hCG in vitro is associated with increased endothelial permeability. Hum Reprod. 2009;24:1191-1199.
29. Soares SR, Gomez R, Simon C, Garcia-Velasco JA, Pellicer A. Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome. Hum Reprod Update. 2008;14: 321-333. (Pubitemid 351858972)
30. Ozcakir HT, Giray SG, Ozbilgin MK, Uyar Y, Lacin S, Caglar H. Immunohistochemical detection of transforming growth factor-alpha, epidermal growth factor, and vascular endothelial growth factor expression in hyperstimulated rat ovary. Acta Obstet Gynecol Scand. 2005;84:887-893. (Pubitemid 41215809)
31. Kamat BR, Brown LF, Manseau EJ, Senger DR, Dvorak HF. Expression of vascular permeability factor/vascular endothelial growth factor by human granulosa and theca lutein cells. Role in corpus luteum development. Am J Pathol. 1995;146:157-165.
32. Greenhill CJ, Rose-John S, Lissilaa R, et al. IL-6 trans-signaling modulates TLR4-dependent inflammatory responses via STAT3. J Immunol. 2011;186:1199-1208.
33. Barkhausen T, Tschernig T, Rosenstiel P, et al. Selective blockade of interleukin-6 trans-signaling improves survival in a murine polymicrobial sepsis model. Crit Care Med. 2011;39:1407-1413.
34. Lee WL, Slutsky AS. Sepsis and endothelial permeability. N Engl J Med. 2010;363:689-691.
35. Kruttgen A, Rose-John S. Interleukin-6 in sepsis and capillary leakage syndrome. J Interferon Cytokine Res. 2012;32:60-65.
36. Maeda A, Goto Y, Matsuda-Minehata F, Cheng Y, Inoue N, Manabe N. Changes in expression of interleukin-6 receptors in granulosa cells during follicular atresia in pig ovaries. J Reprod Dev. 2007;53:727-736. (Pubitemid 47397273)
37. Machelon V, Emilie D, Lefevre A, Nome F, Durand-Gasselin I, Testart J. Interleukin-6 biosynthesis in human preovulatory follicles: some of its potential roles at ovulation. J Clin Endocrinol Metab. 1994;79:633-642. (Pubitemid 24256566)
38. Kawasaki F, Kawano Y, Kosay Hasan Z, Narahara H, Miyakawa I. The clinical role of interleukin-6 and interleukin-6 soluble receptor in human follicular fluids. Clin Exp Med. 2003;3:27-31. (Pubitemid 36649010)
39. Romano M, Sironi M, Toniatti C, et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity. 1997;6:315-325. (Pubitemid 27148598)
40. Modur V, Li Y, Zimmerman GA, Prescott SM, McIntyre TM. Retrograde inflammatory signaling from neutrophils to endothelial cells by soluble interleukin-6 receptor α. J Clin Invest. 1997;100: 2752-2756. (Pubitemid 28007543)